FDA accepts review for Nanoscope’s one-time vision loss gene therapy
Nanoscope Therapeutics announced on 9 Sept. 2026 that the U.S. Food and Drug Administration has accepted and filed its Biologics License Application seeking approval of MOGENRY (sonpiretigene isteparvovec, MCO-010), an intravitreal optogenetic gene therapy for patients with retinitis pigmentosa with
<p>Nanoscope Therapeutics announced on 9 Sept. 2026 that the U.S. Food and Drug Administration has accepted and filed its Biologics License Application seeking approval of MOGENRY (sonpiretigene isteparvovec, MCO-010), an intravitreal optogenetic gene therapy for patients with retinitis pigmentosa with</p>